ClinicalTrials.gg
CompletedNCT05092386Updated Jan 28, 2026

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

A Phase 1 interventional study of Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine and Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13) in Pneumococcal Infections, sponsored by Sinovac Life Sciences Co., Ltd.. Completed at 1 site in China. Open to participants aged 6 Weeks to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Sinovac Life Sciences Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
6 Weeks to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd — 3 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal Infections · Sinovac Biotech Co., Ltd.

Enrollment
8th of 12
310 · median 403
Started
2023
with 1 other
Phase 1
5 of 13
1 open now
Registered
3rd of 13
by date

Among the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 1, and was the 3rd registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

3 of the 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Weeks to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pneumococcal Infections by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

This study is an open-label combined randomized double-blind, positive control phase Ⅰ clinical trial of the a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine manufactured by Sinovac Research \& Development Co., Ltd. The purpose of this study is to preliminary evaluate the safety and immunogenicity of the study vaccine

Read the detailed description

This study is an open-label combined randomized double-blind, positive control phase Ⅰ clinical trial in subjects aged 2 months (minimum 6 weeks) and above. The experimental vaccine was manufactured by Sinovac Research \& Development Co., Ltd. .And one of the positive control vaccine was manufactured by WALVAX Biotechnology Co., Ltd( WALVAX PCV13) ,the other manufactured by Pfizer(Pfizer PCV13).A total of 310 subjects including 20 adults aged 18-49 years,20 adolescents and children aged 6\~7 years ,60 children aged 2-5 years,60 infants aged 12\~23 months,60 infants aged 7 \~11 months,60 infants aged 2 months (minimum 6 weeks), and 30 infants aged 3 months will be enrolled.Subjects will be assigned to receive one dose , two doses ,three doses or four doses of experimental vaccine or different positive control vaccines . Subjects aged 18-49 years will receive one dose of experimental vaccine.Subjects aged 6\~17 years will receive one dose of experimental vaccine.Subjects aged 2\~5 years will be randomly divided into two groups in a ratio of 1:1,and each group will receive one dose of experimental vaccine or control vaccine(WALVAX PCV13).Subjects aged 7 \~ 11 months and subjects aged 12 \~23 months will be randomly divided into two groups in a 1:1 ratio,the subjects aged 12 \~ 23 months will receive two doses of experimental vaccine or control vaccine on the schedule of month 0,2 .Subjects aged 7 \~11 months will receive 3 doses of experimental vaccine or control vaccine (WALVAX PCV13)on the immunization schedule of month 0,2,4.Subjects aged 3 months will receive 4 doses of experimental vaccine.Subjects aged 2 months will be randomly divided into 2 groups in a 1:1 ratio and each group will receive 4 doses of experimental vaccine or control vaccine (Pfizer PCV13).

03

Conditions studied

  • Pneumococcal Infections
04

Who can participate

Ages eligible
6 Weeks to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy infants aged 2 months (minimum 6 weeks), healthy infants aged 3 months, healthy infants aged 7 \~ 11 months, healthy infants aged 12\~ 23 months, healthy children aged 2\~ 5 years, healthy adolescent and children aged 6\~ 17 years, healthy adults aged 18\~ 49 years;
  • Proven legal identification and vaccination certificate (vaccination certificate is required for those aged 5 and below);
  • The subject and/or guardian can understand and voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • Have received pneumococcal polysaccharide vaccine or pneumococcal polysaccharide conjugate vaccine;
  • Have Bacterial pneumonia or invasive pneumococcal infectious disease (IPD) caused by pneumococcus confirmed by sputum culture;
  • History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
  • disease or immunodeficiency / ;
  • Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;
  • Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
  • History of thyroidectomy, absence of spleen, functional absence of spleen, and absence of spleen or splenectomy due to any circumstance;
  • Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal ) or obvious bruising or blood coagulation;
  • Immunosuppressive therapy, cytotoxic therapy, inhaled (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
  • History of alcohol or drug abuse;
  • Receipt of blood products within in the past 3 months;
  • Receipt of other drugs in the past 30 days;
  • Receipt of attenuated in the past 14 days;
  • Receipt of inactivated or subunit vaccines in the past 7 days;
  • Acute diseases or acute exacerbation of chronic diseases in the past 7 days;
  • Axillary temperature >37.0°C;
  • According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Experimental Group of One Dose

    110 Participants (including 20 subjects aged 18\~49 years, 20 subjects aged 6\~17 years , 30 subjects aged2-5 years) will receive one dose of experimental vaccine

    Biological: Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    Experimental Group of Two Doses

    30 Participants aged 12\~23 months will receive two doses of experimental vaccine on the schedule of month 0,2.

    Biological: Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    Experimental Group of Three Doses

    30 Participants aged 7\~11 months will receive two doses of experimental vaccine on the primary immunization schedule of month 0,2 and one dose of booster immunization during the participants aged 12\~15 months .

    Biological: Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Experimental
    Experimental Group of Four Doses

    30 Participants aged 3 months will receive three doses of experimental vaccine on the primary immunization schedule of month 0,1,2 and one dose of booster immunization during the participants aged 12\~15 months ; 30 Participants aged 2 months will receive three doses of experimental vaccine on the primary immunization schedule of month 0,2,4 and one dose of booster immunization during the participants aged 12\~15 months

    Biological: Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    Control Group of One Dose With WALVAX PCV13

    30 Participants aged 2-5 years will receive one dose of control vaccine (WALVAX PCV13)

    Biological: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)

  • Active comparator
    Control Group of Two Doses With WALVAX PCV13

    30 Participants aged 12\~23 months will receive two doses of control vaccine(WALVAX PCV13) on the schedule of month 0,2.

    Biological: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)

  • Active comparator
    Control Group of Three Doses With WALVAX PCV13

    30 Participants aged 7\~11 months will receive two doses of control vaccine(WALVAX PCV13) on the primary immunization schedule of month 0,2 and one dose of booster immunization during the participants aged 12\~15 months .

    Biological: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)

  • Active comparator
    Control Group of Three Doses With Pfizer PCV13

    30 Participants aged 2 months will receive three doses of control vaccine(Pfizer PCV13 on the primary immunization schedule of month 0,2,4 and one dose of booster immunization during the participants aged 12\~15 months

    Biological: Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)

Interventions

  • BiologicalInvestigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

    The investigational vaccine was manufactured by Sinovac Research \& Development Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and diphtheria CRM197 in 0·5 mL of aluminum phosphate ,sodium chloride,polysorbate 80 and succinic acid per injection.

  • BiologicalControl 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13)

    The control vaccine was manufactured by WALVAX Biotechnology Co., Ltd. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,disodium hydrogen phosphate and sodium dihydrogen phosphate per injection.

  • BiologicalControl 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13)

    The control vaccine was manufactured by Pfizer. each for purified 13 serotypes of pneumococcal polysaccharide and tetanus toxoid vector (TT) in 0·5 mL of aluminum phosphate ,sodium chloride ,succinic acid ,polysorbate 80 and water for injection per injection.

06

What researchers measure

Primary outcomes

  1. Safety index-incidence of adverse reactions

    Incidence of adverse reactions 0 to 30 days after each dose of experimental vaccine

    Time frame: Day 0-30 after each dose of experimental vaccine

Secondary outcomes

  1. Safety index-incidence of adverse reactions

    Incidence of adverse reactions 0 to 7 days after each dose of experimental vaccine

    Time frame: Day 0-7 after each dose of experimental vaccine

  2. Safety index-incidence of abnormal indicators

    Incidence of abnormal indicators of Blood routine, blood biochemistry and urine routine 3 days after vaccination in subjects aged 2 years and older

    Time frame: Day 3 after vaccination after each dose of experimental vaccine

  3. Safety index-Incidence of serious adverse events during the safety observation period

    Incidence of serious adverse events during the safety observation period, including 1 month after vaccination in subject aged 6 years and older, and 6 months after primary immunization and 1 month after booster immunization in subject aged 2 months (minimum 6 weeks) to 5 years(if any)

    Time frame: 1 month after vaccination ,6 months after primary immunization or 1 month after booster immunization

  4. Immunogenicity index-Geometric mean concentrations (GMC) and GMI of specific IgG for each serotype

    Geometric mean concentrations (GMC) and GMI of specific IgG for each serotype at 30 days after vaccination in subjects of all age groups

    Time frame: Day 30 after vaccination

  5. Immunogenicity index-Geometric mean titers (GMT) and GMI of serotype specific opsonophagocytic antibody OPA for each serotype

    Geometric mean titers (GMT) and GMI of serotype specific opsonophagocytic antibody OPA for each serotype at 30 days after vaccination in subjects of all age groups

    Time frame: Day 30 after vaccination

  6. Immunogenicity index-Seropositive rates,GMCs and GMI of serum specific antibody

    Seropositive rates of IgG concentration ≥0.35μg/mL, ≥1.0μg/mL, geometric mean concentration (GMCs) and GMI of serum specific antibody at 30 days after primary immunization in subjects of all age groups

    Time frame: Day 30 after vaccination

  7. Immunogenicity index-Proportion of OPA ≥1:8 of each serum and geometric mean titer (GMT)

    Proportion of OPA ≥1:8 of each serum and geometric mean titer (GMT)in subjects of all age groups at 30 days after primary immunization

    Time frame: Day 30 after vaccination

  8. Immunogenicity index-Seropositive rates of IgG concentration ≥0.35μg/mL, ≥1.0μg/mL, geometric mean concentration (GMC)

    Seropositive rates of IgG concentration ≥0.35μg/mL, ≥1.0μg/mL, geometric mean concentration (GMC) in subjects aged 2 months (Minimum 6 weeks), 3 months and 7 \~ 11 months at 30 days before and after booster immunization

    Time frame: Day 30 before and after booster immunization

  9. Immunogenicity index-Proportion of OPA ≥1:8 for each serotype and geometric mean titer (GMT)

    Proportion of OPA ≥1:8 for each serotype and geometric mean titer (GMT) in subjects aged 2 months (Minimum 6 weeks), 3 months, and 7\~ 11 months at 30 days before and after booster immunization

    Time frame: Day 30 before and after booster immunization

07

Study locations

1 site
  • Henan Center for Diseases Control and Prevention
    Zhengzhou, Henan, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in May 2024, 16 months.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2021
First posted
Oct 25, 2021
StartActual
Jan 3, 2023
Primary completionActual
May 26, 2024
CompletionActual
May 28, 2024
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05092386
Responsible party
Sponsor
First posted
Oct 25, 2021
Start date
Jan 3, 2023
Primary completion
May 26, 2024
Completion
May 28, 2024
Last update
Jan 28, 2026

Study contacts

Yanxia Wang, Master
principal investigator · Henan Provincial Center for Disease Prevention and Control

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion